Notification of receipt of response regarding Pre -IND meeting with the US FDA

Tregem Biopharmaceuticals Inc. (Kyoto City, President and CEO: Honoka Kiso; hereinafter referred to as "Tregem") has been holding pre-IND meetings with the U.S. Food and Drug Administration (FDA) for the U.S. development of an antibody drug (development code: TRG-035) for congenital tooth agenesis.
We are pleased to announce that we have now received an official response from the FDA.

20251127_Notification of receipt of response regarding Pre -IND meeting with the US FDA.pdf